Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Purpose: The antibody-drug conjugate glembatumumab vedotin links a fully human immunoglobulin G2 monoclonal antibody against the melanoma-related glycoprotein NMB (gpNMB) to the potent cytotoxin monomethyl auristatin E. This study evaluated the safety and activity of glembatumumab vedotin in patients with advanced melanoma. Patients and Methods: Patients received glembatumumab vedotin every 3 weeks (schedule 1) in a dose escalation and phase II expansion at the maximum-tolerated dose (MTD). Dosing during 2 of 3 weeks (schedule 2) and weekly (schedule 3) was also assessed. The primary end points were safety and pharmacokinetics. The secondary end points included antitumor activity, gpNMB expression, and immunogenicity. Results: One hundred seventeen patients were treated using schedule 1 (n = 79), schedule 2 (n = 15), or schedule 3 (n = 23). The MTDs were 1.88, 1.5, and 1.0 mg/kg for schedules 1, 2, and 3, respectively. Grade 3/4 treatment-related toxicities that occurred in two or more patients included rash, neutropenia, fatigue, neuropathy, arthralgia, myalgia, and diarrhea. Three treatment-related deaths (resulting from pneumococcal sepsis, toxic epidermal necrolysis, and renal failure) occurred at doses exceeding the MTDs. In the schedule 1 phase II expansion cohort (n = 34), five patients (15%) had a partial response and eight patients (24%) had stable disease for ≥ 6 months. The objective response rate (ORR) was 2 of 6 (33%) for the schedule 2 MTD and 3 of 12 (25%) for the schedule 3 MTD. Rash was correlated with a greater ORR and improved progression-free survival. Conclusion: Glembatumumab vedotin is active in advanced melanoma. The schedule 1 MTD (1.88 mg/kg once every 3 weeks) was associated with a promising ORR and was generally well tolerated. More frequent dosing was potentially associated with a greater ORR but increased toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636 · cited 1×
“This design had a type I error rate of 10% and a type II error rate of 10%.(25) If one or more responses were observed among the first 18 patients, an additional 14 patients would be enrolled.”
BackgroundSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Self-citationTomihari, M., Hwang, S., Chung, J., Cruz Jr., P. D., & Ariizumi, K. (2009) · Experimental Dermatology · doi:10.1111/j.1600-0625.2008.00830.x · Cited by 84
Research works printed but not linked: 40
- 10.1056/NEJMoa1200694 · DOI · Paper page
- 10.1056/NEJMoa1103782 · DOI · Paper page
- 10.1056/NEJMoa1002011 · DOI · Paper page
- 10.1056/NEJMoa1203421 · DOI · Paper page
- 10.1056/NEJMoa1003466 · DOI · Paper page
- 10.1056/NEJMoa1200690 · DOI · Paper page
- 10.1002/ijc.2910600111 · DOI · Paper page
- 10.1158/1078-0432.CCR-05-2018 · DOI · Paper page
- 10.1074/jbc.M008539200 · DOI · Paper page
- 10.4049/jimmunol.178.10.6557 · DOI · Paper page
- 10.1615/CritRevEukaryotGeneExpr.v13.i24.180 · DOI
- 10.1016/j.febslet.2008.03.030 · DOI · Paper page
- 10.1158/1078-0432.CCR-09-1611 · DOI · Paper page
- 10.1158/1078-0432.CCR-05-2797 · DOI · Paper page
- 10.1158/1541-7786.MCR-07-0119 · DOI · Paper page
- 10.1074/jbc.M211498200 · DOI · Paper page
- 10.1016/S0168-8278(03)00361-1 · DOI
- 10.1371/journal.pone.0012093 · DOI · Paper page
- 10.1038/nbt832 · DOI · Paper page
- 10.1021/bc800289a · DOI · Paper page
- 10.1093/protein/gzl013 · DOI · Paper page
- 10.1007/s00280-007-0490-z · DOI
- 10.1093/jnci/89.15.1138 · DOI · Paper page
- 10.1007/s002800050726 · DOI
- 10.1111/apm.12107 · doi:10.1111/apm.12107
- 10.1038/srep00573 · DOI · Paper page
- 10.1200/JCO.2010.29.5865 · DOI · Paper page
- 10.1200/JCO.2011.40.5902 · DOI · Paper page
- 10.1056/NEJMoa1002965 · DOI · Paper page
- Williams MD, 2010, Melanoma Res, 20, 184, 10.1097/CMR.0b013e3283364a08 · DOI
- 10.2215/CJN.03390509 · DOI · Paper page
- 10.1182/blood-2006-11-053769 · DOI · Paper page
- 10.4049/jimmunol.179.9.5778 · DOI · Paper page
- 10.1158/0008-5472.CAN-09-2538 · DOI · Paper page
- 10.1002/eji.201041233 · DOI
- 10.1158/0008-5472.SABCS12-P6-10-01 · DOI
- 10.1158/1535-7163.TARG-13-C232 · doi:10.1158/1535-7163.targ-13-c232
- 10.1016/j.molonc.2008.02.002 · DOI
- 10.1371/journal.pone.0061895 · DOI · Paper page
- 10.1593/tlo.12280 · DOI · Paper page
Cited by
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Building better monoclonal antibody-based therapeutics
Weiner, G. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3930 · Cited by 712
Antibody–drug conjugates for cancer therapy
Thomas, A., Teicher, B. A., & Hassan, R. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30030-4 · Cited by 606
Donaghy, H. (2016) · mAbs · doi:10.1080/19420862.2016.1156829 · Cited by 495
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Metadata
- Authors
- Ott, P. A., Hamid, O., Pavlick, A. C., Kluger, H., Kim, K. B., Boasberg, P. D., Simantov, R., Crowley, E., Green, J. A., Hawthorne, T., Davis, T. A., Sznol, M., & Hwu, P.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-11-10
- Volume
- 32
- Issue
- 32
- Pages
- 3659-3666
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2005354746
- Cited by
- 97
- References
- 4
- FWCI
- 4.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.